We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

22 hedge funds and large institutions have $16M invested in NeuBase Therapeutics, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 4

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

66% more capital invested

Capital invested by funds: $9.62M → $16M (+$6.34M)

38% more funds holding

Funds holding: 16 → 22 (+6)

Holders
22
Holders Change
+6
Holders Change %
+37.5%
% of All Funds
0.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
5
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EI
EAM Investors
California
+$586K
2
Renaissance Technologies
Renaissance Technologies
New York
+$561K
3
BlackRock
BlackRock
New York
+$184K
4
Millennium Management
Millennium Management
New York
+$168K
5
JP Morgan Chase
JP Morgan Chase
New York
+$80.6K

Top Sellers

Rank Fund Capital Flow
1
FIA
FNY Investment Advisers
New York
-$97.6K
2
VF
Virtu Financial
New York
-$64K
3
UBS Group
UBS Group
Switzerland
-$19.9K
4
Bank of America
Bank of America
North Carolina
-$1K
5
First Manhattan
First Manhattan
New York
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
GC
1
Greenlight Capital
New York
$11.1M – – –
Renaissance Technologies
2
Renaissance Technologies
New York
$2.54M +$561K +4,784 +37%
EI
3
EAM Investors
California
$719K +$586K +4,993 New
BlackRock
4
BlackRock
New York
$375K +$184K +1,565 +151%
Vanguard Group
5
Vanguard Group
Pennsylvania
$296K – – –
Millennium Management
6
Millennium Management
New York
$206K +$168K +1,433 New
Geode Capital Management
7
Geode Capital Management
Massachusetts
$116K +$1.41K +12 +2%
JP Morgan Chase
8
JP Morgan Chase
New York
$99K +$80.6K +687 New
Qube Research & Technologies (QRT)
9
Qube Research & Technologies (QRT)
United Kingdom
$88K +$71.5K +610 New
ECM
10
ExodusPoint Capital Management
New York
$88K +$71.7K +611 New
HWA
11
Heritage Wealth Advisors
Virginia
$87.1K +$6.45K +55 +10%
Citadel Advisors
12
Citadel Advisors
Florida
$85K +$69.3K +591 New
FAIM
13
Financial Advocates Investment Management
Washington
$72K +$58.6K +500 New
Morgan Stanley
14
Morgan Stanley
New York
$56K +$1.76K +15 +4%
Deutsche Bank
15
Deutsche Bank
Germany
$38K +$31.8K +271 New
FIA
16
FNY Investment Advisers
New York
$4K -$97.6K -832 -96%
SSB
17
Sandy Spring Bank
Maryland
$4K – – –
LTFS
18
Ladenburg Thalmann Financial Services
Florida
$3K – – –
UBS Group
19
UBS Group
Switzerland
$2K -$19.9K -170 -91%
CLOS
20
Compagnie Lombard Odier SCmA
Switzerland
$1K – – –
AA
21
Ancora Advisors
Ohio
$1K +$586 +5 New
AP
22
Americana Partners
Texas
$1K +$1.52K +13 New
VF
23
Virtu Financial
New York
– -$64K -637 Closed
First Manhattan
24
First Manhattan
New York
– -$1K -18 Closed
Bank of America
25
Bank of America
North Carolina
– -$1K -8 Closed
1
2

NBSE Hedge Fund Activity: Q4 2019 in Review

22 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q4 2019, worth a combined $16M — up 66% from $9.62M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new NBSE positions and 4 closed out — a net gain of 6 holders — while 5 added to existing stakes and 2 trimmed.

The largest buyer was EAM Investors, opening a new position worth an estimated $586K. The largest seller was FNY Investment Advisers, cutting an estimated $97.6K.

  • 22 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q4 2019, up from 16 in Q3 2019.
  • Funds reported $16M of NeuBase Therapeutics, Inc. Common Stock stock for Q4 2019, up 66% quarter-over-quarter.
  • 10 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q4 2019 and 4 closed out, a net change of +6 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q4 2019 was EAM Investors, an estimated $586K added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q4 2019 was FNY Investment Advisers, an estimated $97.6K sold.

Based on aggregated 13F filings for Q4 2019.